Axon Enterprise earnings analysis: questions answered and next catalysts

Axon Enterprise (AXON) is $312.79, down 18.24% as of Nov 6, 12:51 PM EST. That is a fresh 52-week low area (range $307.00–$665.07), and the market cap is about $25.3B. The Nasdaq rose 1.7% the same day, so this is a company-specific reaction.

Q3 FY2026 was reported Nov 5. It broke a run of strong prints, and Piper Sandler called it arguably Axon’s worst quarter as a public company.

Axon Enterprise (AXON): Q3 EPS $1.72 vs $1.91 est (-9.95%) || Revenue $908.55M vs $940.02M est (+28% YoY) || Q4 consensus EPS $2.28, revenue $1.06B

Questions Answered

• Is demand intact? Mostly yes. RBC said the three federal Dedrone deals, worth about $130M, were delayed rather than canceled. Procurement timing and election-cycle dynamics are the cause. Piper Sandler does not believe Axon lost business. Both sources are from Nov 6, 2026.
• Is software carrying the growth? Yes. Software and services revenue grew 43%. AI bookings rose 50%, and AI products reached $100M in ARR. Total future contracted revenue rose 39% (Northland, Nov 6, 2026).
• What happened to guidance? FY2026 revenue guidance was cut to roughly $3.61–$3.63B (about 30% growth), from 32–34%. Free cash flow guidance was trimmed to $350–$400M, from $450M, because of inventory builds.

Questions Still Open

• Hardware health: Taser revenue fell 2% YoY, its first decline in years. Product gross margin dropped below 50%, with memory costs a headwind. Management expects Taser to return to growth above 10%, which is not yet proven.
• Bookings target: Needham warned that the 30%-plus normalized five-year bookings target is now at risk.
• Skydio: The $1.2B investment lifts Axon’s stake to 37% and adds a US and Canada exclusive distribution deal. It is strategically sound but capital-intensive, at a time when free cash flow is already being trimmed.
• Guidance credibility: Large Dedrone deals will now be counted only when management is confident they will ship. That could mean lower targets but bigger beats, per Piper Sandler.

Next Catalysts

• Q4 report: Tentatively Mar 2, 2027. Consensus is EPS $2.28 and revenue $1.06B. The implied jump from Q3’s $908.55M relies on deal timing.
• Dedrone deals: The $130M of federal deals are now expected in 2027. Their closing is the clearest upside trigger.
• Taser rebound: Watch whether the hardware return to growth above 10% shows up in results.
• Margins and cash flow: Memory costs and inventory normalization will decide whether the FCF guidance cut was a one-off.
• Analyst targets: The reset was steep: Northland $540 (from $800), RBC $615, Piper $540, Needham $500, Baird $600. All keep positive ratings. Piper expects pressure through year-end but a positive setup into 2027.

Bull vs. Bear

Bull: The delays are timing rather than lost deals, software growth is accelerating, and the stock is down about 46% YTD. Bear: Guidance was cut, hardware margins are under pressure, and the stock has fallen ~27% in a week. Consensus FY2027 EPS of $10.57 (up from $7.68 in FY2026) leaves little room for further slips. Even so, consensus estimates have not been cut: the 30-day EPS revision is +0.83% as of the latest data.

The price figures are intraday and may move. Consensus data is from the earnings overview, and analyst commentary is dated Nov 6, 2026.